當升科技(300073.SZ):2022年管理層與核心骨幹股權增持計劃尚未買入公司股票
格隆匯7月28日丨當升科技(300073.SZ)公吿稱,公司2022年第一次臨時股東大會於2022年6月28日審議通過了《公司2022年管理層與核心骨幹股權增持計劃(草案)》(簡稱“股權增持計劃”)。公司管理層和核心骨幹員工計劃使用不超過人民幣8000萬元通過二級市場購買等方式增持公司股票並鎖定12個月。
截至2022年7月27日,公司已與長江養老保險股份有限公司(簡稱“長江養老”)簽署受託管理合同,委託長江養老為公司該次股權增持計劃設立專項資管產品“長江盛世華章集合型團體養老保障管理產品進取增利6號組合2期”進行管理。該次股權增持計劃目前尚未買入公司股票。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.